Abstract:
본 발명은 동결건조한 정제 봉독을 유효성분으로하는 호흡기 염증성 질환 예방 및 치료용 조성물에 관한 것으로, 상기 봉독은 진균으로 유발된 호흡 상피세포의 염증반응과 집먼지 진드기로 유발된 호흡 상피세포의 염증반응을 효과적으로 억제할 뿐만 아니라, 알레르기 비염 동물모델에서 비강 염증반응을 효과적으로 억제하는 뛰어난 효과가 있으며, 호흡기 염증성 질환 예방 및 치료용 물질로 사용함으로써 국내 양봉농가의 소득원을 창출하고 천연물 신약으로서 봉독에 대한 원천기술을 확보하는 효과가 있다.
Abstract:
PURPOSE: A pharmaceutical composition containing bee venom as an active ingredient for preventing and treating respiratory inflammation is provided to effectively suppress inflammation in the respiratory epithelial cells, caused by fungi and dust mites and to effectively prevent nasal cavity inflammation in an animal model with allergic rhinitis. CONSTITUTION: Bee venom prevents and treats respiratory inflammation and is freeze-dried for intranasal administration. A pharmaceutical composition for preventing and treating respiratory inflammation contains 0.00005-1 ug/ml of bee venom as an active ingredient. A method for determining the recommended dosage of a drug for preventing and treating respiratory inflammation comprises the steps of: isolating bee venom from Apis mellifera L. and freeze-drying the bee venom; applying the freeze-dried bee venom to nasal mucosal endothelial cells in various concentrations to measure the efficacy of the bee venom; treating an animal model with allergic rhinitis with the freeze-dried bee venom in various concentrations; and measuring treatment index and numerical value in respiratory inflammation by a conventional experimental method using blood and nasal cavity tissues collected from an experimental animal treated with the freeze-dried bee venom and determining the recommended dosage.